About this document
Ticagrelor Monotherapy vs Aspirin in ACS by Rodrigo Martin is a document available to read on EtoBox.
1) The TWILIGHT-ACS trial randomized high-risk patients with non-ST elevation acute coronary syndromes (NSTE-ACS) who underwent percutaneous coronary intervention (PCI) to ticagrelor alone or ticagrelor plus aspirin. 2) The primary endpoint was BARC type 2, 3, or 5 bleeding between 0-12 months. Secondary endpoints included non-fatal myocardial infarction, stroke, or death between 0-12 months. 3) Baseline characteristics were well matched between the two treatment groups. The trial aimed to determine if
- Author
- Rodrigo Martin
- Language
- EN